2 registrations that name magnesium citrate as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT05018221
Better Evidence and Translation for Calciphylaxis
Phase 3
University of Sydney
About 350 people
Started Aug 26, 2021
In plain words A Phase 3 study of magnesium citrate in people 18 and older, run by University of Sydney. It plans to enroll about 350 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Calciphylaxis.
Currently receiving haemodialysis, or peritoneal dialysis that can be converted to haemodialysis, with planned ongoing haemodialysis a minimum of three times per week for at least the duration of the protocolised calciphylaxis treatments…
Have a new calciphylaxis ulcer present for less than 10 weeks
Age ≥ 18 years
Eligible for randomisation in at least one recruiting domain
1 more inclusion criterion and the exclusion criteria are on the listing.
This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.
Where, as registered
No US site; Australia (16), New Zealand (5).
RecruitingNCT03088852
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
Phase 4
Frieda Wolf
About 330 people
Started May 10, 2017
In plain words A Phase 4 study of magnesium citrate in people 18 to 90, run by Frieda Wolf. It plans to enroll about 330 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Hypomagnesemia.
Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.
The exclusion criteria are on the listing.
What it tests, as registered
Magnesium Citrate 100 MG
Registered summary
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The full summary is on the listing.